[1] 潘飞, 寿涓, 张冬青. 不同他汀类药物治疗非酒精性脂肪性肝病合并高脂血症患者效果分析. 实用肝脏病杂志,2022,25(5):665-668. [2] 李彩银,郭淑霞,李毓,等. 新疆生产建设兵团农村维吾尔族居民非酒精性脂肪性肝病的发病情况和影响因素分析. 中华流行病学杂志,2024,45(8):1149-1157. [3] 周冷潇,张卿,高鹰,等. 成人血脂异常与非酒精性脂肪性肝病发病风险的前瞻性队列研究. 中华全科医师杂志,2024,23(8):831-838. [4] Li R, Li Y, Yang X, et al. Reducing VEGFB accelerates NAFLD and insulin resistance in mice via inhibitingAMPK signaling pathway.J Transl Med, 2022, 20(1):341. [5] Ma HK, Wang YM, Guo MP,et al. Effectiveness of acupoint application in patients with pharyngeal pain:evidence from CHUNBO, a prospective real-world study. Chin J Integr Med, 2024, 30(1):18-24. [6] Wang Z, Sun T, Yu J,et al. FGF21:a sharp weapon in the process of exercise to improve NAFLD.Front Biosci (Landmark Ed), 2023, 28(12):351-351. [7] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. NAFLD防治指南(2018年更新版). 实用肝脏病杂志,2018,21(2):177-186. [8] 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版). 中华全科医师杂志,2017,16(1):15-35. [9] 郭萌, 郭琦, 张峰. 超声瞬时弹性成像检测受控衰减参数评估非酒精性脂肪性肝病患者肝脂肪变程度价值研究. 实用肝脏病杂志,2024,27(2):189-192. [10] 刘亚杰, 王睿林. 血清锰与非酒精性脂肪性肝病的相关性研究. 中国临床研究,2024,37(6):901-907. [11] Xue Y, Peng Y, Zhang L,et al.Effect of different exercise modalitieson nonalcoholic fatty liver disease:a systematic review and network meta-analysis. Sci Rep, 2024, 14 (1):6212. [12] 李亚梅.穴位贴敷疗法对90例高血压合并高脂血症患者血压及血脂水平的影响.中华高血压杂志,2015,23(1):386-386. [13] 李颖,黄明星. 运动处方联合饮食干预对非酒精性脂肪性肝病患者身体形态和血液生化指标的影响. 中国慢性病预防与控制,2021,29(2):115-118. [14] Chen Y, Luo S, Luo M. Efficacy and safety of buzhongyiqi decoction combined with acupoint application for functional constipation in elderly people:A systematic review and meta-analysis. Medicine (Baltimore), 2024, 103(3):e36579. [15] Keating SE, Sabag A, Hallsworth K, et al. Exercise in the management of metabolic-associated fatty liver disease(MAFLD) in adults:A position statement from exercise and sport science australia. Sports Med, 2023, 53(12):2347-2371. [16] Zhu W. Effective roles of exercise and diet adherence in non-alcoholic fatty liver disease. World J Gastroenterol, 2024, 30(29):3456-3460. [17] Chen L, Lei Y, Lu C,et al. Punicic acid ameliorates obesity-related hyperlipidemia and fatty liver in mice via regulation of intestinal flora and lipopolysaccharide-related signaling pathways.Food Funct, 2024, 15(9):5012-5025. [18] Xie H, Zhang X, Tian D,et al. Effect of acupoint application of Chinese medicine combined with a hot compress on pain of uterine and fallopian tube contrast agent in infertile women. Altern Ther Health Med, 2024, 30(9):65-71. [19] Simon TG, Wilechansky RM, Stoyanova S, et al. Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: A randomized clinical trial.JAMA, 2024,331(11):920-929. [20] Feng G, Valenti L, Wong VW, et al. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease.Nat Rev Gastroenterol Hepatol, 2024,21(1):46-56. |